EGFR and non-small cell lung carcinoma: A retrospective study involving 304 patients with EGFR-mutated NSCLC showed that among the 116 patients receiving osimertinib and the 188 patients receiving first- or second-generation EGFR-TKIs, osimertinib treatment reduced the incidence of LM by 67%,and osimertinib treatment was an independent significant indicator of reduced LM incidence (8).